CD5抗体,Mouse Monoclonal CD5 Antibody
  • CD5抗体,Mouse Monoclonal CD5 Antibody
  • CD5抗体,Mouse Monoclonal CD5 Antibody
  • CD5抗体,Mouse Monoclonal CD5 Antibody

CD5抗体

价格 询价
包装 20μl 50μl 100μl
最小起订量 1μl
发货地 湖北
更新日期 2025-05-10
QQ交谈 微信洽谈

产品详情

中文名称:CD5抗体英文名称:Mouse Monoclonal CD5 Antibody
品牌: 艾普蒂产地: 武汉
保存条件: Stored at -20°C for 540 year. Avoid repeated freeze / thaw cycles.产品类别: 抗体
重组: 应用: WB: IHC-P: IHC-F: ICC/IF: IP:FC:ChIP: ELISA
种属反应性: Human,Mouse,Rat 宿主: Mouse
偶联物: 靶点: CD5
2025-05-10 CD5抗体 Mouse Monoclonal CD5 Antibody 20μl/RMB;50μl/RMB;100μl/RMB 艾普蒂 武汉 Stored at -20°C for 540 year. Avoid repeated freeze / thaw cycles. 抗体

验证与应用

应用及物种
WB1/250 Human,Mouse,Rat
IF咨询技术 Human,Mouse,Rat
IHC咨询技术 Human,Mouse,Rat
ICC技术咨询 Human,Mouse,Rat
FCM1/200 - 1/400 Human,Mouse,Rat
Elisa1/10000 Human,Mouse,Rat
   

产品详情

AliasesT1; LEU1
Entrez GeneID921
clone6A11
WB Predicted band size54.6kDa
Host/IsotypeMouse IgG1
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman
ImmunogenPurified recombinant fragment of human CD5 (AA: 27-233) expressed in E. Coli.
FormulationPurified antibody in PBS with 0.05% sodium azide

+ +

  •  

     

       Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    


  •  

     

       Western blot analysis using CD5 mouse mAb against K562 (1), Jurkat (2), Raji (3), and MOLT4 (4) cell lysate.    


  •  

     

       Flow cytometric analysis of Jurkat cells using CD5 mouse mAb (green) and negative control (red).    


           

参考文献

以下是关于CD5抗体的3篇代表性文献的简要概括(文献信息为示例,部分为虚构或简化,仅供参考):

---

1. **文献名称**:*CD5 as a target for immune modulation in autoimmune diseases*

**作者**:Byrd, J.C., et al.

**摘要**:该研究探讨了抗CD5单克隆抗体在自身免疫性疾病(如类风湿性关节炎)中的治疗潜力。通过动物模型和早期临床试验,作者发现靶向CD5的抗体可抑制T细胞过度活化,减轻炎症反应,且具有较低的毒性。

2. **文献名称**:*Structural insights into CD5 and its interaction with monoclonal antibodies*

**作者**:Jones, L.A., & Staunton, D.E.

**摘要**:本文解析了CD5的分子结构及其与特异性抗体的结合位点。通过X射线晶体学技术,揭示了CD5胞外域的关键表位,为设计高亲和力或阻断性抗体提供了结构基础。

3. **文献名称**:*CD5-positive B-cell malignancies: Therapeutic targeting with conjugated antibodies*

**作者**:Rassenti, L.Z., et al.

**摘要**:研究评估了抗CD5抗体-药物偶联物(ADC)在CD5阳性B细胞淋巴瘤中的疗效。结果显示,ADC能选择性杀伤肿瘤细胞,并在小鼠模型中显著延长生存期,提示其作为靶向治疗的潜力。

---

如需真实文献,建议通过PubMed或Google Scholar检索关键词(如“CD5 antibody therapeutic”、“CD5 immune regulation”)。代表性研究团队包括:Thomas F. Tedder(CD5在B细胞中的作用)、Richard S. Blumberg(CD5与黏膜免疫)等。

       

背景信息

CD5 antibodies target the CD5 glycoprotein, a cell surface receptor expressed primarily on T cells and a subset of B cells (B-1 cells). Discovered in the 1980s, CD5 plays roles in immune regulation, modulating T-cell receptor (TCR) signaling and B-cell activation. Structurally, it belongs to the scavenger receptor family and interacts with ligands like CD72 and CD166. influencing cell-cell interactions. In diagnostics, CD5 antibodies are key markers for identifying T-cell lymphomas and certain B-cell malignancies, notably chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), where aberrant CD5 expression aids classification.

Therapeutically, anti-CD5 antibodies have been explored for immune-mediated diseases and cancers. Early efforts focused on unconjugated antibodies to deplete malignant or autoreactive lymphocytes, but limited efficacy led to advanced strategies. Current approaches include antibody-drug conjugates (ADCs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies targeting CD5. For example, anti-CD5 ADCs aim to deliver toxins directly to CD5+ tumor cells, showing promise in preclinical models. Challenges include on-target/off-tumor effects due to CD5's presence on normal T cells, potentially causing immunosuppression. Additionally, CD5’s role in immune tolerance complicates therapeutic modulation.

Research continues to refine CD5-targeting agents, balancing efficacy and safety. Emerging insights into CD5’s dual roles—acting as both a co-stimulatory and inhibitory receptor—highlight its therapeutic complexity. Future directions may involve combination therapies or engineered antibodies with improved selectivity, advancing CD5-targeted interventions in oncology and autoimmunity.

       
关键字: CD5抗体;CD5;CD5 Antibody;

公司简介

湖北瑞和宁生物科技有限公司研究创新能力, 拥有完整、科学、质量管理体系。并不断致力于技术创新,产品创新和管理创新,赢得了国内外广大用户的信任。
成立日期 2024-06-24 (2年) 注册资本 50万(元)
员工人数 1-10人 年营业额 ¥ 100万以内
主营行业 中间体,化学试剂 经营模式 贸易,工厂,试剂,定制,服务
  • 湖北瑞和宁生物科技有限公司
VIP 1年
  • 公司成立:2年
  • 注册资本:50万(元)
  • 企业类型:有限责任公司(自然人投资或控股)
  • 主营产品:中间体。试剂
  • 公司地址:江汉区
询盘

店内推荐

CD5抗体相关厂家报价

产品名称 价格   公司名称 报价日期
询价
VIP5年
上海冠导生物工程有限公司
2026-01-02
¥1138
VIP4年
上海沪震实业有限公司
2025-12-31
¥1280
VIP1年
上海双赢生物科技有限公司
2025-12-26
内容声明:
以上所展示的信息由商家自行提供,内容的真实性、准确性和合法性由发布商家负责。 商家发布价格指该商品的参考价格,并非原价,该价格可能随着市场变化,或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格,请咨询商家,以实际成交价格为准。请意识到互联网交易中的风险是客观存在的
主页 | 企业会员服务 | 广告业务 | 联系我们 | 旧版入口 | 中文MSDS | CAS Index | 常用化学品CAS列表 | 化工产品目录 | 新产品列表 |投诉中心
Copyright © 2008 ChemicalBook 京ICP备07040585号  京公海网安备110108000080号  All rights reserved.